137 related articles for article (PubMed ID: 38280268)
1. Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil.
de Almeida GMR; de Araujo RS; Castrillo BB; Silva GD; Fortini I; Gonçalves MRR; Castro LHM; Tatsui NH; Adoni T; Sato DK; Apóstolos-Pereira SL; Callegaro D
J Neuroimmunol; 2024 Mar; 388():578295. PubMed ID: 38280268
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders.
Gonzalez C; Vargas D; Contreras K; Garcia P; Rodriguez P; Zarco L; Navas C
Ther Apher Dial; 2022 Dec; 26(6):1274-1280. PubMed ID: 35353437
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource-Limited Settings: Outcomes in a Multiethnic Single-Center Population.
Ong ZM; Schee JP; Viswanathan S
Ther Apher Dial; 2020 Jun; 24(3):312-323. PubMed ID: 31654607
[TBL] [Abstract][Full Text] [Related]
4. Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder.
Viswanathan S; Schee JP; Omar MA; Hiew FL
Ther Apher Dial; 2021 Aug; 25(4):513-532. PubMed ID: 33029928
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders-Experience from Tertiary Care Center in North India.
Hans R; Prakash S; Sharma RR; Sankhyan N; Takkar A; Goyal M; Saikia B; Lal V; Marwaha N
Neurol India; 2022; 70(2):710-713. PubMed ID: 35532644
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee.
Ipe TS; Raval JS; Fernando LP; Gokhale A; Jacquot C; Johnson AD; Kim HC; Monis GF; Mo YD; Morgan SM; Pagano MB; Pham HP; Sanford K; Schmidt AE; Schwartz J; Waldman A; Webb J; Winters JL; Wu Y; Yamada C; Wong ECC
J Clin Apher; 2020 Jan; 35(1):25-32. PubMed ID: 31705563
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
Siritho S; Nopsopon T; Pongpirul K
J Neurol; 2021 Dec; 268(12):4549-4562. PubMed ID: 33037886
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Ariel B; Castillo MC; Cristiano E; Diégues Serva GB; Dos Santos AC; Finkelsteyn AM; López PA; Patrucco L; Molina O; Pettinicchi JP; Toneguzzo V; Caride A; Rojas JI
J Neurol; 2020 May; 267(5):1260-1268. PubMed ID: 31932911
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
[TBL] [Abstract][Full Text] [Related]
11. Status of the neuromyelitis optica spectrum disorder in Latin America.
Rivera VM; Hamuy F; Rivas V; Gracia F; Rojas JI; Bichuetti DB; Villa AM; Marques VD; Soto A; Bertado B; Frenk IT; Galleguillos L; Quiñones J; Ramirez DA; Caparó-Zamalloa C; Ciampi E; Lana-Peixoto MA; Rodríguez E; Zarco L; Sinay V; Armas E; Becker J; Benzadón A; Lopez E; Carnero Contentti E; Correa-Diaz EP; Diaz A; Fleitas CV; Playas G; Molina O; Rojas E; Sato D; Soto I; Céspedes JV; Correale J; Barboza A; Monterrey P; Candelario A; Tavolini DR; Parajeles A; Pujol BS; Diaz de la Fe A; Alonso R; Bolaña C; Guzman MK; Carrá A; Gamarra OG; Raggio JV; Rodriguez LC; Ramirez NE; Ordoñez L; Skromne E; Portillo LL; Canabal AP; Weiser R; Sirias V; Calderón RF; Cornejo EA; Hernández M; Quiroz JCD; Garcia LA; Cedeño CO; Martínez J; Abad-Herrera P
Mult Scler Relat Disord; 2021 Aug; 53():103083. PubMed ID: 34171682
[TBL] [Abstract][Full Text] [Related]
12. Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.
Carnero Contentti E; Soto de Castillo I; Daccach Marques V; López PA; Antunes Barreira A; Armas E; de Aquino Cruz C; Rubstein A; Lavigne Moreira C; Molina OM; Soto A; Tkachuk V
Mult Scler Relat Disord; 2018 Feb; 20():109-114. PubMed ID: 29367170
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
[TBL] [Abstract][Full Text] [Related]
14. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
[TBL] [Abstract][Full Text] [Related]
15. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
Demuth S; Guillaume M; Bourre B; Ciron J; Zephir H; Sirejacob Y; Kerbrat A; Lebrun-Frenay C; Papeix C; Michel L; Laplaud D; Vukusic S; Maillart E; Cohen M; Audoin B; Marignier R; Collongues N;
J Neuroinflammation; 2022 Mar; 19(1):62. PubMed ID: 35236386
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis.
Deng S; Lei Q; Lu W
Front Immunol; 2021; 12():800666. PubMed ID: 35069584
[TBL] [Abstract][Full Text] [Related]
17. Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica.
Ma C; Wang S; Wang G; Wu Y; Yang T; Shen W; Zhuang Y; Zhang L; Liu X; Yang L; Feng Y; Yu Y; Liu Z; Wang D
J Clin Apher; 2020 Jun; 35(3):206-216. PubMed ID: 32240559
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil.
Fukuda TG; Silva ITF; Dos Santos TSS; Filho MBP; de Abreu FF; Oliveira-Filho J
BMC Neurol; 2022 Mar; 22(1):95. PubMed ID: 35296261
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
Palace J; Lin DY; Zeng D; Majed M; Elsone L; Hamid S; Messina S; Misu T; Sagen J; Whittam D; Takai Y; Leite MI; Weinshenker B; Cabre P; Jacob A; Nakashima I; Fujihara K; Pittock SJ
Brain; 2019 May; 142(5):1310-1323. PubMed ID: 30938427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]